Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Teva (TEVA) downgraded to Neutral from Outperform at Credit Suisse. 2. Vitamin Shoppe (VSI) downgraded to Underweight from Equal Weight at Barclays with analyst Karen Short raising her price target for the shares to $10 from $4. 3. Dover (DOV) downgraded to Market Perform from Outperform at BMO Capital with analyst R. Scott Graham citing valuation. 4. T. Rowe Price (TROW) downgraded to Hold from Buy at Deutsche Bank with analyst Brian Bedell saying through August, trends are worsening for active managers and T. Rowe Price has posted weaker performance relative to peers. 5. Reliance Steel (RS) double downgraded to Underperform from Buy at BofA/Merrill with analyst Timna Tanners saying he is cautious over late cycle earnings. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

Baird raised the firm's price target on Dover to $208 from $185 and keeps an Outperform rating on the shares after its Q1 earnings beat. The company "healthily" beat consensus while its growth outpaced expectations and the management's guidance was narrowed to the high end of the range, the analyst tells investors in a research note. Order commentary was also encouraging, with the company expecting positive yoy growth for the remainder of the year, the firm added.

Reliance expects a better than normal seasonal recovery in demand in the second quarter of 2024 despite prevailing macroeconomic uncertainty and geopolitical matters. Accordingly, the company estimates its tons sold will be up 2.5% to 4.5% in the second quarter of 2024 compared to the first quarter of 2024, with approximately 2% of the sequential growth coming from recently completed acquisitions on April 1, 2024. In addition, Reliance expects its average selling price per ton sold for the second quarter of 2024 to be down 1% to 3% compared to the first quarter of 2024. The company also anticipates short term gross profit margin pressure in the second quarter of 2024 as it works through higher cost inventory on hand. Based on these expectations, the company anticipates non-GAAP earnings per diluted share in the range of $4.70 to $4.90 for the second quarter of 2024.